BioRestorative suspends ExoCR and BioX product shipments pending regulatory review

BioRestorative Therapies, Inc.

Suspended all orders and shipments of ExoCR and BioX biocosmeceutical product lines effective August 7, 2026.
Suspension pending business review and regulatory assessment of documentation, sourcing, and regulatory status.
Company has not decided to discontinue these product lines.
Review could result in costs, need for additional capital, and uncertainty about resuming sales.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.